Home » Business News » 2013 » May » May 29, 2013

Medigene Receives Further European Patent on EndoTAG®-1

May 29, 2013 - London

Medigene AG /Medigene Receives Further European Patent on EndoTAG®-1. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Martinsried/Munich, 29 May 2013. Medigene AG (Frankfurt, Prime Standard; MDG) announced today that the European Patent Office has granted a further patent which protects the drug candidate EndoTAG®-1. The term of the patent EP 2108362 entitled "A cationic liposomal preparation comprising a taxane" ends on June 26, 2023.

Dr. Frank Mathias, Chief Executive Officer of Medigene AG: "The new patent strengthens the patent position for EndoTAG®-1 in Europe. We will continue to extend our patent portfolio to ensure protection of the EndoTAG®-1 product for Medigene and our partner SynCore."

About EndoTAG®-1: The clinical drug candidate EndoTAG®-1 is a novel composition of the established cytostatic drug paclitaxel combined with neutral and positive lipids. Because of the positively charged lipids, EndoTAG®-1 interacts with newly developed, negatively charged endothelial cells, which are particularly required for the generation of tumor blood vessels. The EndoTAG®-1 paclitaxel component attacks the endothelial cells as they divide, thus targeting the blood supply to tumors without affecting the blood supply to healthy tissue. By doing this, EndoTAG®-1 is expected to prevent the formation of new tumor blood vessels and to inhibit tumor growth. Medigene has successfully completed two clinical phase II trials of EndoTAG®-1 in pancreatic cancer and triple-negative breast cancer (TNBC). The drug candidate has also shown positive results in a recently concluded investigator-initiated trial (IIT) in HER2-negative breast cancer.  

Medigene AG (Frankfurt: MDG, prime standard) is a publicly listed biotechnology company headquartered in Martinsried/Munich, Germany. Medigene focuses on clinical research and development of novel drugs against cancer and autoimmune diseases. Medigene is the first German biotech company to have revenues from a marketed product (Veregen®), which is distributed by partner companies. Medigene has two drug candidates in clinical trials, EndoTAG®-1 and RhuDex®, and is developing an innovative vaccine technology. For more information, please visit

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® and EndoTAG® are registered trademarks of Medigene AG. These trademarks may be owned or licensed in select locations only.


Julia Hofmann, Claudia Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01

To unsubscribe from the press release distribution list, please go to

Press release as PDF

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Medigene AG via Thomson Reuters ONE



Comment on this story